在一些乳腺癌患者中,Vepdegestrant表现出有希望,但在更广泛的试验中却落后。 Vepdegestrant shows promise in some breast cancer patients but falls short in broader trials.

一项实验性乳癌药物(Vepdegestrant)在最近的第三阶段试验中显示结果好坏参半。 An experimental breast cancer drug, vepdegestrant, showed mixed results in a recent Phase 3 trial. 它改善了具有特定基因突变(ESR1)的患者的无进展生存,但并未改善更广泛的患者群体中的无进展生存。 It improved progression-free survival in patients with a specific genetic mutation (ESR1) but not in the broader patient group. 该药物针对雌激素受体阳性、HER2-阴性晚期乳癌,该药物普遍得到良好治疗。 The drug, which targets estrogen receptor-positive, HER2-negative advanced breast cancer, was generally well-tolerated. 详细结果将在今年晚些时候的医学会议上与监管当局分享。 Detailed results will be shared with regulatory authorities and at a medical conference later this year.